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The reaction of mesangial cells with aberrantly glycosylated
IgA1 has been implicated in the etiology of
IgA nephropathy (IgAN). Tumor necrosis factor, which is
assumed to mediate the interaction between mesangial cells
and podocytes, also induces the expression of platelet-
activating factor (PAF). In this study, we determined whether
PAF affects the expression of nephrin (an adhesion molecule
critical to glomerular permselectivity) and cytoskeletal
F-actin organization in podocytes. We treated human
mesangial cells with atypically glycosylated IgA1 either
prepared in vitro or derived from the sera of patients with
IgAN. We then prepared conditioned media from these cells
and added them to cultured human podocytes in the
presence of PAF receptor antagonists. Podocytes transfected
to overexpress acetylhydrolase, the main catabolic enzyme of
PAF, served as controls. Downregulation of nephrin
expression and F-actin reorganization occurred when
podocytes were cultured with mesangial cell-conditioned
medium. Preincubation of podocytes with a PAF receptor
antagonist prevented the loss and redistribution of nephrin.
In control podocytes overexpressing acetylhydrolase,
nephrin loss was abrogated. Our results suggest that
atypically glycosylated IgA-induced PAF from mesangial cells
is a mediator of podocyte changes, which, when more
directly tested elsewhere, were found to be associated with
proteinuria. Hence, it is possible that these in vitro findings
may be relevant to the proteinuria of IgAN.
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A clue to the pathogenesis of IgA nephropathy (IgAN) is
thought to be the mesangial deposition of circulating
aberrantly glycosylated IgA1.1 IgA1 is heavily glycosylated,
with O-glycosylated carbohydrate chains based on N-acetyl
galactosamine (GalNAc) residues, usually extended with
galactose (Gal) to form Galb1,3GalNAc, which may be
covered with a-2,6 and/or a-2,3 sialic acid (Sia). Several
authors reported the presence of aberrantly glycosylated IgA,
with reduced Gal and/or Sia and increased exposure of
GalNAc, in sera of patients with IgAN.2–5 Desialylated and
degalactosylated IgA (deSial/deGal IgA) have been proven to
react with mesangial cells (MCs) and to trigger the synthesis
of mediators of inflammation and sclerosis through mod-
ifications of integrin expression and proliferation/apo-
ptosis.5–8
Hematuria is the most common early clinical manifesta-
tion of IgAN. When proteinuria develops, the progression
toward renal failure is accelerated, and proteinuria is
considered as the most powerful risk factor for progression
of IgAN.9 Investigations on the mechanisms leading to the
development of proteinuria in IgAN have focused on
podocytes after finding a loss of podocytes in the urine of
these patients, with podocytopenia related to the severity of
glomerular dysfunction and secondary to unknown podocyte
insults.10,11 A downregulation of nephrin, a transmembrane
adhesion molecule expressed at the slit diaphragm of podo-
cytes, has been shown to have a critical role in glome-
rular permselectivity.12 Nephrin has a structural function in
podocyte architecture, and also has the capacity to transfer
signals from the podocyte surface to cytoskeleteton.13,14 Actin
cytoskeleton modification with loss of stress fibers has been
reported in monolayers of cultured podocytes with altered
permeability to albumin, mimicking proteinuric condi-
tions.15 Besides the inherited nephrotic syndrome sustained
by mutations of nephrin,16 a reduction in nephrin expression
has also been shown in primary glomerular diseases with
nephrotic-range proteinuria.17–19 Nephrin and other podo-
cyte markers, including ezrin and podocin,20 as well as
glomerular epithelial protein 1,21 have been recently reported
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to be downregulated in mild forms of IgAN and to correlate
with proteinuria.
In IgAN, a cross-talk between MCs and podocytes has
been postulated as a mechanism relevant for the development
of proteinuria. In an in vitro model of incubation of
podocytes with supernatants of MCs cultured with deSial/
deGal IgA or with IgA isolated from sera of patients with
IgAN, a loss of nephrin expression and a cytoskeleton protein
downregulation have been shown in human glomerular
epithelial cells (GECs) (Coppo R et al. J Am Soc Nephrol 2007;
18: 626A). Lai et al.20,22 reported that humoral factors
(predominantly tumor necrosis factor-a (TNF-a) and
transforming growth factor-b) released from MCs are
responsible for nephrin loss from podocytes.
Platelet-activating factor (PAF) may act as a secondary
mediator of TNF-a.23 Moreover, several studies showed
that PAF may enhance glomerular permeability, and that
TNF-a induced the synthesis of PAF from MCs.24–27
The aim of this study was to investigate whether
supernatants of MCs incubated with aberrantly glycosylated
IgA or with sera from IgAN patients induced nephrin loss
from cultured human podocytes and whether this effect was
mediated by PAF.
RESULTS
Supernatants of MCs stimulated with deSial/deGal
polymeric IgA or with IgA1 isolated from patients with
IgAN-induced loss of nephrin expression by GECs
Desialylated and degalactosylated polymeric IgA (pIgA) and
aberrantly glycosylated IgA1 isolated from sera of patients
were removed after 24 h of incubation with MCs, substituted
with fresh medium, which was recovered after an additional
12 or 24 h, and incubated with GECs to avoid direct contact
between IgA and GECs. The expression of nephrin on
nonpermeabilized GECs was evaluated by indirect immuno-
fluorescence using a monoclonal antibody (mAb) specific for
its extracellular domain. The staining for nephrin showed a
fine punctuated pattern on the surface of GECs (Figure 1a).
Aberrantly glycosylated IgA did not directly induce loss of
nephrin by GECs (not shown). In contrast, when GECs were
stimulated for 1 h with supernatants of MCs previously
challenged with deSial/deGal pIgA (Figure 1d and f) or with
aberrantly glycosylated IgA1 isolated from patients with
IgAN (Figure 2d, e and f), a loss of nephrin was observed, as
indicated by the decrease in immunofluorescence staining
intensity. The supernatants recovered from MCs incubated
with native pIgA or IgA1 isolated from healthy controls
did not induce a downregulation of nephrin expression
(Figures 1b, c, e, and g). The effect of supernatants from MCs
incubated with IgA1 from patients with IgAN was signifi-
cantly greater than when incubated with IgA1 from healthy
controls (Table 1 and Figure 2h). No correlation was found
with individual levels of proteinuria. The loss of nephrin
induced by aberrantly glycosylated IgA was confirmed by
western blot (Figure 1 and 2h) and fluorescence-activated cell
sorting analysis (Figure 3).
Supernatants of MCs stimulated with aberrantly
glycosylated IgA induced F-actin redistribution in GECs
As the loss of nephrin was previously shown to be associated
with cytoskeleton redistribution,15,28 we studied the effect of
supernatants from MCs incubated with deSial/deGal pIgA, as
described above, on the organization of F-actin. The super-
natants of conditioned MCs induced cytoskeleton reorgani-
zation, with loss of stress fibers and the cortical accumulation
of F-actin associated with cell retraction (Figure 4).
Supernatants of MCs stimulated with native pIgA had no
detectable effect on F-actin staining.
Role of PAF in mediating the loss of nephrin
Tumor necrosis factor-a has been recently suggested to be
involved in mediating the cross-talk between MCs and GECs
induced by abnormally glycosylated IgA.20,22 As PAF is
known to mediate several of the effects of TNF-a,23 we
investigated whether the effect of the supernatant of MCs
incubated with aberrantly glycosylated IgA was mediated by
PAF. TNF-a, but not deSial/deGal pIgA, induced a time-
dependent and dose-dependent synthesis of PAF by GECs
(Figures 5a and b). In turn, GECs expressed a PAF receptor
(Figure 5g), and when incubated with synthetic PAF, showed
a downregulation in the expression of nephrin (Figure 5c, d
and h), suggesting a paracrine effect of PAF. This down-
regulation was abrogated by the PAF receptor antagonist,
WEB2170 (Figure 6). When GECs were stimulated with the
supernatant of MCs stimulated with deSial/deGal pIgA, in
the presence of WEB2170, the loss of nephrin was abrogated
(Figure 6b and e). Similar results were obtained when GECs
were incubated with supernatants derived from incubation of
MCs with aberrantly glycosylated IgA1 isolated from sera of
IgAN patients (Figure 6h, k and n).
To further demonstrate the role of PAF, we generated a
PAF-deficient GEC line by transfecting cells with a vector
carrying the cDNA for human plasmatic PAF acetylhydrolase
(PAF-AH), the main catabolic enzyme of PAF (PAF-AH
GECs). In PAF-AH GECs, no significant loss of nephrin
occurred on stimulation with supernatants of MCs previously
conditioned by aberrantly glycosylated IgA, either prepared
in vitro (Figure 6f) or isolated from patients with IgAN
(Figure 6i, l and o), as well as with synthetic PAF (Figure 5e, f
and h). In control GECs transfected with an empty vector, the
loss of nephrin occurred as in wild-type GECs.
PAF receptors and nephrin expression on podocytes
in renal biopsies and PAF-AH levels in sera of patients
with IgAN
As shown in Figure 7a, we confirmed the expression of the
PAF receptor in podocytes in vivo in biopsy samples of
patients with IgAN. To evaluate whether the mechanism
described in vitro also occurs in IgAN patients, we studied
nephrin expression and serum PAF-AH activity, which is
considered to be a marker of enhanced PAF synthesis.29 We
found that nephrin expression in renal biopsy samples was
significantly reduced in patients with IgAN developing
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proteinuria (seven cases), but not in nonproteinuric patients
(six cases) (Figure 7b–d). Moreover, we found that PAF-AH
activity was increased in sera of IgAN patients developing
proteinuria, compared with 10 healthy controls (Figure 7e).
DISCUSSION
In this study, we report a downregulation of nephrin
expression associated with a modification in cytoskeletal
organization in human podocytes cultured with supernatants
of MCs stimulated with aberrantly glycosylated IgA generated
in vitro or isolated from sera of patients with IgAN.
Nephrin has a crucial role in the filtrating barrier and in
protein glomerular permselectivity. The redistribution and
loss of nephrin induced by genetic mutation or immune-
mediated stimuli have been correlated with the development
of proteinuria and nephrotic syndrome in humans and
experimental models;16,30–33 a reduction of nephrin expres-
sion has also been shown in primary acquired nephrotic
syndromes.17–19 Here, we show that nephrin was significantly
downregulated in IgAN patients with proteinuria. This result
is in line with previous studies in IgAN showing either the
absence of nephrin reduction in patients without proteinur-
ia19 or a nephrin downregulation correlated with proteinur-
ia.20,22 Moreover, in this study, we demonstrate that MCs
incubated with aberrantly glycosylated IgA induced loss of
nephrin from cultured human podocytes. This effect was not
because of the aberrantly glycosylated IgA per se, as their
incubation with GECs did not induce a loss of nephrin and as
the glycosylated IgA molecules were washed out from MCs
before recovering supernatants for GEC incubation. These
results suggest that mediators released from MCs are
responsible for nephrin downregulation. Previous studies
demonstrated a striking connection between cytoskeleton
and nephrin.13–15,18,19 Indeed, a number of different media-
tors affect cytoskeleton redistribution and shedding of
nephrin from the cell surface, which was abrogated by
blockade of cytoskeleton activation.15,17,18 Loss of nephrin
was not observed when experiments were performed with
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Figure 1 | Effect of native polymeric IgA (pIgA) or desialylated and degalactosylated pIgA (deSial/deGal) on podocyte (glomerular
epithelial cell, GEC) monolayers. After 24 h of incubation of mesangial cells (MCs) with various IgA preparations, IgA-containing
supernatants were removed, MCs were washed with medium and cultured for an additional 12 h (in some experiments, for 24 h). The
culture medium was then recovered and incubated for 1 h with GECs. This procedure avoided a direct contact between GECs and IgA. (a–f)
Representative micrographs of nephrin expression detected by immunofluorescence in control GECs (a), or in GECs incubated with
supernatants of MCs conditioned with IgA1 isolated from a healthy subject (b), or in GECs conditioned with pIgA and recovered after 12 h
(c) or 24 h (e) after medium change, or with deSial/deGal pIgA recovered after 12 h (d) or 24 h (f) after medium change. Original
magnification  630. (g) Semiquantitative analysis of nephrin expression evaluated as relative fluorescence intensity after GEC incubation
with vehicle alone (Ctr) or with supernatants of MCs challenged with IgA1 isolated from healthy subjects, or with pIgA or aberrantly
glycosylated pIgA (deSial/deGal pIgA), for 12 or 24 h. Data are expressed as mean±s.d. of five different experiments. ANOVA (analysis of
variance) with Newmann–Keuls multicomparison test was performed: *Po0.05 deSial/deGal pIgA 12 h versus pIgA 12 h; #Po0.05 deSial/
deGal pIgA 24 h versus pIgA 24 h. (h) Western blot analysis for nephrin and b-actin expression on podocytes treated for 1 h with vehicle
alone (Ctrl), or with supernatants of MCs conditioned with pIgA or deSial/deGal pIgA and recovered after 12 or 24 h.
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IgA1 isolated from healthy controls, suggesting that altered
IgA molecules are responsible for MC stimulation. The
observation that the effect of IgA from sera of patients with
IgAN was reproducible by the in vitro-prepared deSial/deGal
IgA further stresses the role of the composition of
carbohydrate moieties of the IgA molecule.
At variance with studies on plasma permeability fac-
tors from patients with idiopathic focal and segmental
glomerulosclerosis,33,34 wherein the effect was direct on
podocytes, in this study, mediators released from MCs were
the effectors of nephrin loss. This result indicated a cross-
talk between the different cell types present in glomeruli.
Indeed, we recently found that sera of patients with gestosis
induced a loss of nephrin by triggering the release of
endothelin 1 from glomerular endothelial cells, which in
turn activated the cytoskeleton of podocytes and redis-
tribution of nephrin.32 Lai et al.20,22 suggested that TNF-a
produced by MCs is a critical mediator for the loss of
nephrin. Specific neutralizing antibodies against TNF-a
abolished the effect of MCs incubated with pIgA isolated
from IgAN patients.
Platelet-activating factor, a phospholipid mediator of cell-
to-cell communication that belongs to the structurally related
family of acetylated phosphoglycerides, acts as a secondary
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Figure 2 | Effect of aberrantly glycosylated IgA1 isolated from sera of patients with IgA nephropathy (IgAN) on nephrin expression
by glomerular epithelial cells (GECs). (a–f) Representative micrographs of nephrin expression detected by immunofluorescence in control
GECs (a), or in GECs treated for 1 h with conditioned medium from mesangial cells (MCs) stimulated for 24 h with native polymeric IgA
(pIgA) (b), degalactosylated pIgA (deSial/deGal pIgA) (c) or with aberrantly glycosylated IgA1 isolated from sera of three representative
patients with IgAN (d–f). Original magnification  630. (g) Semiquantitative analysis of nephrin expression evaluated as relative fluorescence
intensity after podocyte stimulation with conditioned medium recovered from MCs treated with vehicle alone (Ctr), native pIgA (pIgA),
deSial/deGal pIgA or with aberrantly glycosylated IgA1 isolated from sera of three representative IgAN patients (p1, p2, p3). Data are expressed
as mean±s.d. of five different experiments. ANOVA (analysis of variance) with Newmann–Keuls multicomparison test was performed:
*Po0.05 deSial/deGal pIgA and sera from IgAN patients versus control podocytes. (h) Densitometric analysis and representative western blot
of nephrin protein levels in lysates of control podocytes (lane 1, Ctr) or in those treated with conditioned medium from MCs stimulated for
24 h with aberrantly glycosylated IgA1 isolated from sera of p1, p2, p3 IgAN patients (lanes 2, 3 and 4), or from sera of a healthy subject (lane 5),
in those treated with conditioned medium from MCs stimulated with deSial/deGal pIgA (lane 6) and with native pIgA (lane 7). Data are
expressed as mean±s.d. of three different experiments. ANOVA with Newmann–Keuls multicomparison test was performed: *Po0.05 sera
from IgAN patients versus healthy controls or deSial/deGal pIgA versus control podocytes.
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mediator for several cytokines and growth factors, including
TNF-a.34,35 In the setting of glomerular injury in IgAN, PAF
could be synthesized by several cell types, including MCs and
infiltrating inflammatory cells.36 Indeed, we found that GECs
were able to synthesize PAF after stimulation with TNF-a,
and not with deSial/deGal IgA, further supporting the fact
that PAF could mediate, at least in part, the effects of TNF-a
on podocytes in an autocrine loop. To investigate its role in
the cross-talk between MCs and GECs induced by aberrantly
glycosylated IgA, we used two different approaches. As we
found that podocytes express the PAF receptor in vitro and
in vivo, we used a PAF receptor antagonist, which was shown
to prevent the loss of nephrin induced by the supernatant of
MCs. Second, as GECs lack the expression of the main
catabolic enzyme of PAF, PAF-AH, we generated transfectants
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Figure 3 | Flow cytometric analysis of downmodulation of nephrin expression in glomerular epithelial cells (GECs).
(a–f) Representative flow cytometric analysis of GECs (black histograms; white histograms represent isotypic controls) incubated for 1 h
with medium alone (a), or with conditioned medium recovered from mesangial cells (MCs) treated with native polymeric IgA (pIgA)
(b), degalactosylated pIgA (deSial/deGal pIgA) (c) or with aberrantly glycosylated IgA1 isolated from sera of three representative IgA
nephropathy (IgAN) patients (d–f). (g) Semiquantitative analysis of nephrin expression detected as percentage mean fluorescence in control
podocytes and in podocytes treated for 1 h with conditioned medium recovered from MCs treated with native pIgA, deSial/deGal pIgA or
with aberrantly glycosylated IgA1 isolated from sera of three representative IgAN patients (p1, p2, p3). Data are expressed as mean±s.d.
of seven different experiments. ANOVA (analysis of variance) with Newmann–Keuls multicomparison test was performed: *Po0.05
deSial/deGal pIgA and sera from IgAN patients versus control podocytes.
Table 1 | Nephrin expression on cultured podocytes (GECs)
after stimulation with conditioned medium recovered from
mesangial cells treated with vehicle alone or with IgA1
isolated from healthy controls or from patients with IgAN
Mesangial cell
conditioning
Nephrin: percentage of
positive GECs
Nephrin: mean relative
fluorescence intensity
Vehicle 98 40
IgA1 from healthy
subjects
97.1±1.7 37.0±16.1
IgA1 from IgAN
patients
90.0±0.53** 27.1±0.88*
Abbreviations: GEC, glomerular epithelial cell; IgAN, IgA nephropathy.
Results of flow cytometry analysis are expressed as percentage of positive cells
and as mean relative fluorescence intensity. Data are expressed as mean±standard
deviation.
**Po0.04 and *Po0.05: significance of the difference of the effect obtained
with IgA1 from healthy subjects.
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expressing this enzyme. PAF-AH expression by GECs abrogated
the effect of the supernatants of MCs and that of synthetic PAF.
These results suggest that PAF is critical for the effect of the
supernatants of MCs on nephrin loss. Previous studies have
shown that PAF induces a rearrangement of cell cytoskeleton in
several cell types, including MCs and podocytes.24–26 Recently,
we showed that PAF-induced cytoskeletal redistribution is
involved in the enhanced glomerular permeability induced by
HIV-Tat.28 Moreover, serum and urine PAF and PAF-AH levels
were shown to be increased in patients with glomerulonephri-
tides, including IgAN.29 In this study, we showed that PAF-AH
activity was increased in sera of IgAN patients with proteinuria,
possibly by virtue of substrate (PAF) availability. The role of
PAF in glomerulonephritides is further supported by studies
showing that PAF receptor antagonists or PAF-AH prevent
enhanced glomerular permeability in experimental models.37,38
In conclusion, the results of this study indicate that
MCs are activated by contact with aberrantly glycosylated
IgA1 isolated from patients with IgAN, and produce soluble
mediators that downregulate the expression of nephrin and
induce rearrangement of F-actin, which is fundamental in
maintaining the podocyte spatial structure. Experiments of
PAF receptor blockade and of enhanced PAF catabolism
suggest that PAF mediated these effects.
MATERIALS AND METHODS
Study design
Human MCs were incubated with aberrantly glycosylated IgA1
isolated from sera of IgAN patients, with IgA1 from healthy controls
and with deSial/deGal IgA obtained by treating in vitro pIgA with
selected glycosidases. After 24 h of incubation, IgA-containing
supernatants were removed, and MCs were washed and cultured
in standard medium for an additional 12 h (24 h in some experi-
ments). The culture medium was then recovered and incubated for
1 h with GECs. GECs were assessed for nephrin and F-actin, in the
absence or presence of a PAF receptor antagonist. GECs transfected
to overexpress PAF-AH, the main catabolic enzyme of PAF, were
used in control experiments.
Isolation of IgA1 from sera of patients and controls
Immunoglobulins were isolated from individual sera by ammonium
sulfate precipitation (2.1 mol/l final concentration) at 4 1C for 12 h
and dissolved in 0.175 mol/l Tris-HCl (pH 7.5). The obtained
fraction was incubated with agarose (Sigma, St Louis, MO, USA)
conjugated with the lectin jacalin (specific for GalNac-Gal residues,
peculiar of IgA1 carbohydrate chains) at room temperature (RT) for
12 h to allow lectin–sugar affinity interaction. After washing the
coated agarose in Tris-HCl, the IgA1 fraction was eluted using
0.8 mol/l Gal and dialyzed to remove free sugar. Purified IgA1
samples were stored at 801C until use.
Detection of aberrantly glycosylated IgA1
Aberrantly glycosylated IgA1 was detected by increased binding to
lectins specific for GalNAc residues (Helix aspersa, -HA- and Vicia
villosa, -VV-), indicating a reduced sialylation and galactosylation of
IgA1 carbohydrate side chains. Briefly, microplates (Grenier,
Frickenhausern, Germany) were coated with preparations of
purified IgA1 isolated by jacalin–agarose columns. After washes,
50 ml of biotinylated lectins (HA (Sigma) 2mg/ml, and VV (Vector,
Burlingame, CA, USA)) was added and incubated for 2 h at RT.
Thereafter, 50 ml of alkaline phosphatase–streptavidin conjugate
(Sigma; 2.5mg/ml) was added and incubated for 2 h at RT. After
washes, 50 ml of phosphatase substrate (P-nitrophenyl phosphate,
Sigma) was added and the absorbance at 405 nm was read on a Bio-
Rad microplate reader (Bio-Rad, Segrate, Milan, Italy) in the linear
phase of the enzymatic reaction.
Subjects tested
In 50 healthy controls, the median values of serum IgA1 binding to
HA and to VV were 0.38 (range 0.09–0.63) OD and 0.22 (0.18–0.25)
OD, respectively. Patients with values exceeding the 90th centile for
healthy controls (40.75 OD for HA or 431 OD for VV), hence
showing signs of an increased exposure of GalNac residues, were
considered positive for aberrantly glycosylated IgA1.
IgA1 from sera of 13 IgAN patients showing increased bindings
to HA and VV lectins, purified by agarose–jacalin columns and IgA1
isolated from sera of 10 healthy controls matched for age and sex,
with normal tests values, were added to MCs in culture.
The clinical features of the 13 patients with IgAN selected for this
investigation are summarized in Table 2. Each subject had aberrantly
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Figure 4 | Effect of native polymeric IgA (pIgA) or
degalactosylated pIgA (deSial/deGal pIgA) on podocyte
cytoskeleton distribution. (a–c) Representative micrographs of
F-actin distribution of glomerular epithelial cell (GEC) monolayers
after incubation with medium alone (a) or with conditioned
medium recovered from mesangial cells (MCs) treated with native
pIgA (b) or deSial/deGal pIgA (c). There was a clear effect of
cytoskeleton reorganization, with loss in stress fibers and cell
retraction. In cells incubated with the supernatants of MCs
cultured with native pIgA, no effect was detectable, and F-actin
staining was similar to that of unstimulated GECs. F-actin was
stained with fluorescein isothiocyanate–phalloidin (original
magnification  630). (d) Semiquantitative analysis of F-actin
expression detected as relative fluorescence intensity after
podocyte stimulation with medium alone or with conditioned
medium recovered from MCs treated with native pIgA or deSial/
deGal pIgA. Data are expressed as mean±s.d. of five different
experiments. ANOVA (analysis of variance) with Newmann–Keuls
multicomparison test was performed: *Po0.05 deSial/deGal pIgA
versus control podocytes.
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glycosylated circulating IgA1 with increased exposure of GalNAc
(detected by abnormally high binding to both HA and VV) and
proteinuria, varying from trace amounts to 3 g/day (seven had
proteinuria 40.3 g/day and were considered proteinuric). None had
severely impaired renal function. None of the healthy subjects
investigated had abnormally elevated levels of IgA1 binding to HA
and VV.
The study was performed in accordance with the declaration of
Helsinki and was approved by the ethical committee of our hospital.
Patients and controls gave their consent for blood collection.
Enzymatic modification of carbohydrate side chain
residues of human polymeric IgA to generate
deSial/deGal IgA
Human polymeric IgA (Sigma) was treated with neuraminidase and
b-galactosidase as described.6
Culture of human MCs
Mesangial cells were obtained as previously described5 and cultured
in RPMI 1640 medium containing 10% fetal calf serum.
Culture of human GECs
Primary cultures of GECs were established and characterized as
previously described.39 GECs showed positive staining for synapto-
podin, Wilm’s tumor antigen, podocalyxin, zonula occludens-1,
cytokeratin, vimentin and laminin; negative staining for smooth
muscle-type myosin, factor VIII and CD45; and cytotoxicity in
response to puromycin aminonucleoside. Established lines of
differentiated GECs were obtained by infection of primary cultures
with a hybrid Adeno5/SV40 virus, as previously described39 and
characterized as above. The GEC line was cultured in Dulbecco’s
modified Eagle’s medium containing 25 mmol/l glucose and 10%
inactivated fetal calf serum.
MC conditioning
Mesangial cells were incubated for 24 h at 37 1C with 50mg/ml of IgA1
isolated from IgAN patients and controls or with 50mg/ml of pIgA or
in vitro-prepared deSial/deGal pIgA, as described in Amore et al.5,
Peruzzi et al.7 and Amore et al.8 After incubation, IgA-containing
supernatants were removed, MCs were washed with medium and
cultured in RPMI containing 0.25% bovine serum albumin for an
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Figure 5 |Role of platelet-activating factor (PAF) in nephrin loss. (a, b) PAF synthesis (expressed as ng per 106 cells) by cultured
glomerular epithelial cells (GECs) stimulated for 10, 20, 30 and 60 min with tumor necrosis factor-a (TNF-a) (10 ng/ml) (a) or stimulated
for 30 min with different doses of TNF-a (b). Data are expressed as mean±s.d. of three different experiments. (c, d) Representative
micrographs of nephrin expression in control GECs (c) and in GECs treated for 1 h with 10 ng/ml of synthetic PAF (d) that induced nephrin
loss. (e, f) Representative micrographs of nephrin expression in PAF acetylhydrolase (PAF-AH) GECs (e) and in PAF-AH GECs stimulated for
1 h with 10 ng/ml of synthetic PAF (f) showing no loss of nephrin ((c–f) Original magnification  630). (h) Semiquantitative analysis of
nephrin expression detected as relative fluorescence intensity after podocyte (dark column) or PAF-AH GEC (white column) stimulation with
medium alone or with 10 ng/ml of synthetic PAF for 1 h. (g) Flow cytometric analysis showing the expression of PAF receptor on GECs (dark
area; white area represents the isotypic control). Data are expressed as mean±s.d. of three different experiments. Student’s t-test was
performed: *Po0.05 control podocytes treated with synthetic PAF versus control podocytes.
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Figure 6 |Abrogation of nephrin downregulation induced by degalactosylated polymeric IgA (deSial/deGal pIgA) and by sera from
IgA nephropathy (IgAN) patients in glomerular epithelial cells (GECs) treated with platelet-activating factor (PAF) receptor
antagonist or WEB2170, and in PAF acetylhydrolase (PAF-AH) GECs. (a, d, g, j, m) Representative micrographs showing nephrin
expression in control GECs (a) or in GECs treated for 1 h with conditioned medium recovered from mesangial cells (MCs) stimulated for 24 h
with deSial/deGal pIgA (d) or with aberrantly glycosylated IgA1 isolated from sera of three representative IgAN patients (g, j, m); (b, e, h, k,
n) representative micrographs showing nephrin expression in GECs previously treated with PAF receptor antagonist WEB2170 and
stimulated with vehicle (b) or treated for 1 h with conditioned medium recovered from MCs stimulated for 24 h with deSial/deGal pIgA (e) or
treated with aberrantly glycosylated IgA1 isolated from sera from IgAN patients (h, k, n); (c, f, i, l, o) representative micrographs showing
nephrin expression in control PAF-AH-transfected podocytes (c) or in PAF-AH-transfected podocytes treated for 1 h with conditioned
medium recovered from MCs stimulated for 24 h with deSial/deGal pIgA (f) or with aberrantly glycosylated IgA1 isolated from sera of IgAN
patients (i, l, o). Original magnification  630. (p) Semiquantitative analysis of nephrin expression detected as relative fluorescence intensity
in normal GECs, in GECs after treatment with PAF receptor antagonist WEB2170 and in PAF-AH-transfected podocytes treated for 1 h with
conditioned medium recovered from MCs stimulated for 24 h with deSial/deGal pIgA or with aberrantly glycosylated IgA1 isolated from sera
of three representative IgAN patients. Data are expressed as mean±s.d. of five different experiments. ANOVA (analysis of variance) with
Newmann–Keuls multicomparison test was performed: *Po0.05 deSial/deGal pIgA and sera from IgAN patients versus control podocytes.
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additional 12 h (in some experiments for 24 h). Thereafter, the culture
medium was collected and incubated for 1 h with GECs.
Transfection of podocytes with PAF-AH
Human immortalized GECs were transfected with acetylhydrolase, as
previously described,39 using a plasmidic DNA (pcDNA4/TO/mys-His
A (5.1 kb)) vector (Invitrogen, Carlsbad, CA, USA) expressing human
plasmatic PAF-AH cDNA. As a control, GECs were transfected with an
empty vector. A stable line of PAF-AH-expressing GECs and a GEC line
transfected with an empty vector were used for the experiments.
The expression of PAF-AH was tested by reverse-transcription
PCR using previously described PAF-AH mRNA-specific primers:
forward, 50-TGTTTCCACTGGGTGATGAA-30 and reverse, 50-TGCC
AGTTGCAAAGTGAAG-30. PAF-AH activity was tested using
a colorimetric assay based on the hydrolysis of 2-thio PAF (Cayman
Chemical, Ann Arbor, MI, USA).
Immunofluorescence studies
Glomerular epithelial cells were plated in an eight-well Permanox slide
(EuroClone, Milan, Italy) at a density of 50,000 cells per well in
Dulbecco’s modified Eagle’s medium containing 10% fetal calf serum.
After washing, cells were incubated for 1 h with supernatants of MCs
previously conditioned with various IgA preparations or medium
alone. Cells were then fixed in 3.5% paraformaldehyde containing 2%
sucrose for 15 min at 4 1C. In some experiments, GECs were incubated
with PAF receptor antagonist WEB 2170 (5mmol/l; Boehringer,
Ingelheim, Germany). Cells were incubated for 60 min at 4 1C with
mAbs that specifically recognize the extracellular domain of nephrin
(GP-N1 Progen Biotechnik GmbH, Heidelberg, Germany; 10mg/ml),
followed by incubation for 30 min at RT with Alexa Fluor 488 anti-
guinea pig IgG (Molecular Probes, Leiden, The Netherlands).
Control experiments included incubation of cells with nonimmune
isotypic control antibodies, followed by the appropriate labeled
secondary antibodies. To evaluate F-actin microfilament, GECs were
fixed after stimulation, permeabilized by incubation for 5 min at
4 1C in HEPES-Triton X-100 buffer and stained for 30 min at 37 1C
with fluorescin isothiocyanate-labeled phalloidin (2 mg/ml; Sigma).
Hoechst 33258 dye (Sigma) was added for nuclear staining.
Kidney sections from renal biopsy samples of IgAN patients and
from five kidney donors were deparaffinized, rehydrated and subjected
to antigen retrieval. Slides were blocked and labeled overnight with a
1:100 dilution of mAbs that specifically recognize the intracellular
domain of nephrin (GP-N2, Progen Biotechnik GmbH; 10mg/ml), or
with polyclonal anti-PAF-R antibody (Santa Cruz Biotechnology,
Santa Cruz, CA, USA), followed by incubation for 30 min at RT with
Alexa Fluor 488 anti-guinea pig or anti-goat IgG (Molecular Probes).
Hoechst 33258 dye (Sigma) was added for nuclear staining.
Confocal microscopy analysis was performed using a Zeiss
LSM 5 Pa model confocal microscope (Carl Zeiss International,
Go¨ttingen, Germany). Nephrin expression was analyzed semiquan-
titatively by measuring fluorescence intensity.
Flow cytometry
Glomerular epithelial cells were grown in six-well plates in
Dulbecco’s modified Eagle’s medium containing 25 mmol/l glucose
supplemented with 10% fetal calf serum to form a confluent
monolayer. Cells were incubated for 1 h with 500ml of supernatants
of MCs challenged with aberrantly glycosylated IgA. Supernatants
were removed and cells were detached with a nonenzymatic
solution, fixed in 4% paraformaldehyde and incubated for 1 h with
an anti-nephrin antibody. After washing, cells were incubated for
30 min with the appropriate fluorescein isothiocyanate-conjugated
antibody. Surface expression of the PAF receptor on GECs was
evaluated by flow cytometry using a murine anti-PAF receptor mAb,
kindly provided by Marek Rola-Pleszczynski (Sherbrooke, Quebec,
Canada).28 The analysis was performed using a FACSCalibur
cytometer (Becton Dickinson, Franklin Lakes, NJ, USA), counting
at least 10,000 events using CellQuest software (Becton Dickinson).
Western blot analysis
Glomerular epithelial cells were lysed at 4 1C for 30 min in a lysis
buffer (50 mmol Tris-HCl (pH 8.3), containing 1% Triton X-100,
1 mmol phenylmethylsulphonyl fluoride, 2 mg/ml leupeptin, 2 mg/ml
aprotinin and 2 mmol sodium orthovanadate) and centrifuged at
15,000 g. For the detection of nephrin, which is contained within
lipid raft microdomains, the lysis buffer was supplemented with
20 mmol CHAPS (3-((3-cholamidopropyl)-dimethylammonio)-1-
propanesulfonate; Sigma). Electrophoresis of cell lysates (150 mg of
protein per lane) and western blot analysis were performed as
previously described,28 using an anti-nephrin antibody (GP-N2;
Progen Biotechnic) or an anti-b-actin mAb (Santa Cruz Biotech-
nology) with the appropriate secondary antibody.
PAF synthesis and PAF-AH activity
To evaluate PAF synthesis, cells were equilibrated for 15 min in
Tris-buffered Tyrode containing 0.25% delipidized bovine serum
albumin (fraction V) and incubated at 37 1C for the indicated
time periods with different doses of TNF-a in Dulbecco’s
modified Eagle’s medium containing 0.25% bovine serum
albumin. Cell pellets were extracted with formic acid added to
lower the pH of the aqueous phase to 3.0. Each individual
experiment was carried out in triplicate. PAF was quantified after
extraction and purification by thin layer chromatography
(60F254 silica gel plates; Merck, Whitehouse Station, NJ, USA)
and high-pressure liquid chromatography (Porasil column;
Millipore-Waters, Billerica, MA, USA), by an aggregation of
washed rabbit platelets.28
Platelet-activating factor acetylhydrolase activity was evaluated
by a colorimetric assay using 2-thio PAF as a substrate for
PAF-AH (Cayman Chemical Company). On hydrolysis of the acetyl
thioester bond at the sn-2 position by PAF-AH, free thiols were
detected using 5,50-dithio-bis-(2-nitrobenzoic acid) (DTNB; Ell-
man’s reagent). After the addition of substrate solution, absorbances
were read once every minute at 414 nm and plotted as a function
of time. The following formula was used to calculate PAF-AH
activity:
PAF-AH activity¼ (DA414/min/10.66 mmol/l) (0.225 ml/0.01 ml)¼
mmol/min/ml, where 10.66 mmol/l is the DTNB extinction coefficient.
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Statistical analysis
Data were collected from three to seven independent experiments
and presented as mean±s.d. Differences between multiple groups
were analyzed by means of ANOVA (analysis of variance) with
Newmann–Keuls. Student’s t-test was used to compare two series of
data. A P-value of o0.05 was considered significant.
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